Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges
The article offers a comparative analysis of the influence of cost-effectiveness thresholds in the decision-making processes in financing policies, coverage, and price regulation of health technologies in nine countries. We investigated whether countries used cost-effectiveness thresholds for public...
Gespeichert in:
Veröffentlicht in: | Applied health economics and health policy 2024-11, Vol.22 (6), p.797-804 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 804 |
---|---|
container_issue | 6 |
container_start_page | 797 |
container_title | Applied health economics and health policy |
container_volume | 22 |
creator | Espinosa, Oscar Rodríguez-Lesmes, Paul Romano, Giancarlo Orozco, Esteban Basto, Sergio Ávila, Diego Mesa, Lorena Enríquez, Hernán |
description | The article offers a comparative analysis of the influence of cost-effectiveness thresholds in the decision-making processes in financing policies, coverage, and price regulation of health technologies in nine countries. We investigated whether countries used cost-effectiveness thresholds for public health policy decision making and found that few countries have adopted the cost-effectiveness threshold as an official criterion for financing, reimbursement, or pricing. However, in countries where it is applied, such as Thailand, the results have been very favorable in terms of minimizing health technology prices and ensuring the financial sustainability of the health system. Although the cost-effectiveness threshold has opportunities for improvement, particularly in certain institutional contexts and with adequate participation of the different strategic actors in the formulation of public policy, its potential use and added value are significant in various aspects. |
doi_str_mv | 10.1007/s40258-024-00900-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11470905</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3079172397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-41d1d428935e8edb4c0a58c45a82662e47bd53c486ed7b6b52d0ff1b098193073</originalsourceid><addsrcrecordid>eNp9UU1v3SAQRFGjJk37B3KokHrphQYw2NBLFT2lTaVIfYfk0BPCsH52xDMp2JHy74vz0nwdemGRdnZmdgehY0a_MEqbkywol4pQLgilmlIi99AhY40mTOn6zf1fEllLfoDe5XxNKa9rLd6ig0ppLYXmh-j3VQYcO7yKeSJnXQduGm5hhJzxZZ8g9zH4jIcRn4MNU-9sArye2zA4vI7lvfuK1ylu0jJgR49XvQ0Bxg3k92i_syHDh4d6hK6-n12uzsnFrx8_V6cXxBUXExHMMy-40pUEBb4VjlqpnJBWFbccRNN6WTmhavBNW7eSe9p1rKVaMV3RpjpC33a8N3O7Be9gnJIN5iYNW5vuTLSDedkZh95s4q1hTDTlbLIwfH5gSPHPDHky2yE7CMGOEOdsiopmDa_0IvbpFfQ6zmks-5mKMaXkskhB8R3KpZhzgu7RDaNmic7sojMlOnMfnVlcfHy-x-PIv6wKoNoBcmmVC6cn7f_Q_gV5WqRP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118852893</pqid></control><display><type>article</type><title>Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges</title><source>MEDLINE</source><source>PAIS Index</source><source>SpringerNature Journals</source><creator>Espinosa, Oscar ; Rodríguez-Lesmes, Paul ; Romano, Giancarlo ; Orozco, Esteban ; Basto, Sergio ; Ávila, Diego ; Mesa, Lorena ; Enríquez, Hernán</creator><creatorcontrib>Espinosa, Oscar ; Rodríguez-Lesmes, Paul ; Romano, Giancarlo ; Orozco, Esteban ; Basto, Sergio ; Ávila, Diego ; Mesa, Lorena ; Enríquez, Hernán</creatorcontrib><description>The article offers a comparative analysis of the influence of cost-effectiveness thresholds in the decision-making processes in financing policies, coverage, and price regulation of health technologies in nine countries. We investigated whether countries used cost-effectiveness thresholds for public health policy decision making and found that few countries have adopted the cost-effectiveness threshold as an official criterion for financing, reimbursement, or pricing. However, in countries where it is applied, such as Thailand, the results have been very favorable in terms of minimizing health technology prices and ensuring the financial sustainability of the health system. Although the cost-effectiveness threshold has opportunities for improvement, particularly in certain institutional contexts and with adequate participation of the different strategic actors in the formulation of public policy, its potential use and added value are significant in various aspects.</description><identifier>ISSN: 1175-5652</identifier><identifier>ISSN: 1179-1896</identifier><identifier>EISSN: 1179-1896</identifier><identifier>DOI: 10.1007/s40258-024-00900-5</identifier><identifier>PMID: 38995492</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Clinical decision making ; Clinical outcomes ; Comparative analysis ; Cost analysis ; Cost-Benefit Analysis ; Costs ; Decision making ; Effectiveness ; GDP ; Gross Domestic Product ; Health Administration ; Health care expenditures ; Health care policy ; Health disparities ; Health Economics ; Health policy ; Health Policy - economics ; Health technology assessment ; Humans ; Medicine ; Medicine & Public Health ; Opportunity costs ; Pharmacoeconomics and Health Outcomes ; Policy Making ; Price regulations ; Pricing policies ; Public Health ; Public Policy ; Quality of Life Research ; Review ; Review Article ; Thailand</subject><ispartof>Applied health economics and health policy, 2024-11, Vol.22 (6), p.797-804</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>Copyright Springer Nature B.V. Nov 2024</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c389t-41d1d428935e8edb4c0a58c45a82662e47bd53c486ed7b6b52d0ff1b098193073</cites><orcidid>0000-0003-4893-0509 ; 0000-0003-1058-3062</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40258-024-00900-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40258-024-00900-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27866,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38995492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Espinosa, Oscar</creatorcontrib><creatorcontrib>Rodríguez-Lesmes, Paul</creatorcontrib><creatorcontrib>Romano, Giancarlo</creatorcontrib><creatorcontrib>Orozco, Esteban</creatorcontrib><creatorcontrib>Basto, Sergio</creatorcontrib><creatorcontrib>Ávila, Diego</creatorcontrib><creatorcontrib>Mesa, Lorena</creatorcontrib><creatorcontrib>Enríquez, Hernán</creatorcontrib><title>Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges</title><title>Applied health economics and health policy</title><addtitle>Appl Health Econ Health Policy</addtitle><addtitle>Appl Health Econ Health Policy</addtitle><description>The article offers a comparative analysis of the influence of cost-effectiveness thresholds in the decision-making processes in financing policies, coverage, and price regulation of health technologies in nine countries. We investigated whether countries used cost-effectiveness thresholds for public health policy decision making and found that few countries have adopted the cost-effectiveness threshold as an official criterion for financing, reimbursement, or pricing. However, in countries where it is applied, such as Thailand, the results have been very favorable in terms of minimizing health technology prices and ensuring the financial sustainability of the health system. Although the cost-effectiveness threshold has opportunities for improvement, particularly in certain institutional contexts and with adequate participation of the different strategic actors in the formulation of public policy, its potential use and added value are significant in various aspects.</description><subject>Clinical decision making</subject><subject>Clinical outcomes</subject><subject>Comparative analysis</subject><subject>Cost analysis</subject><subject>Cost-Benefit Analysis</subject><subject>Costs</subject><subject>Decision making</subject><subject>Effectiveness</subject><subject>GDP</subject><subject>Gross Domestic Product</subject><subject>Health Administration</subject><subject>Health care expenditures</subject><subject>Health care policy</subject><subject>Health disparities</subject><subject>Health Economics</subject><subject>Health policy</subject><subject>Health Policy - economics</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Opportunity costs</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Policy Making</subject><subject>Price regulations</subject><subject>Pricing policies</subject><subject>Public Health</subject><subject>Public Policy</subject><subject>Quality of Life Research</subject><subject>Review</subject><subject>Review Article</subject><subject>Thailand</subject><issn>1175-5652</issn><issn>1179-1896</issn><issn>1179-1896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>7TQ</sourceid><recordid>eNp9UU1v3SAQRFGjJk37B3KokHrphQYw2NBLFT2lTaVIfYfk0BPCsH52xDMp2JHy74vz0nwdemGRdnZmdgehY0a_MEqbkywol4pQLgilmlIi99AhY40mTOn6zf1fEllLfoDe5XxNKa9rLd6ig0ppLYXmh-j3VQYcO7yKeSJnXQduGm5hhJzxZZ8g9zH4jIcRn4MNU-9sArye2zA4vI7lvfuK1ylu0jJgR49XvQ0Bxg3k92i_syHDh4d6hK6-n12uzsnFrx8_V6cXxBUXExHMMy-40pUEBb4VjlqpnJBWFbccRNN6WTmhavBNW7eSe9p1rKVaMV3RpjpC33a8N3O7Be9gnJIN5iYNW5vuTLSDedkZh95s4q1hTDTlbLIwfH5gSPHPDHky2yE7CMGOEOdsiopmDa_0IvbpFfQ6zmks-5mKMaXkskhB8R3KpZhzgu7RDaNmic7sojMlOnMfnVlcfHy-x-PIv6wKoNoBcmmVC6cn7f_Q_gV5WqRP</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Espinosa, Oscar</creator><creator>Rodríguez-Lesmes, Paul</creator><creator>Romano, Giancarlo</creator><creator>Orozco, Esteban</creator><creator>Basto, Sergio</creator><creator>Ávila, Diego</creator><creator>Mesa, Lorena</creator><creator>Enríquez, Hernán</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>7TQ</scope><scope>DHY</scope><scope>DON</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4893-0509</orcidid><orcidid>https://orcid.org/0000-0003-1058-3062</orcidid></search><sort><creationdate>20241101</creationdate><title>Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges</title><author>Espinosa, Oscar ; Rodríguez-Lesmes, Paul ; Romano, Giancarlo ; Orozco, Esteban ; Basto, Sergio ; Ávila, Diego ; Mesa, Lorena ; Enríquez, Hernán</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-41d1d428935e8edb4c0a58c45a82662e47bd53c486ed7b6b52d0ff1b098193073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Clinical decision making</topic><topic>Clinical outcomes</topic><topic>Comparative analysis</topic><topic>Cost analysis</topic><topic>Cost-Benefit Analysis</topic><topic>Costs</topic><topic>Decision making</topic><topic>Effectiveness</topic><topic>GDP</topic><topic>Gross Domestic Product</topic><topic>Health Administration</topic><topic>Health care expenditures</topic><topic>Health care policy</topic><topic>Health disparities</topic><topic>Health Economics</topic><topic>Health policy</topic><topic>Health Policy - economics</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Opportunity costs</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Policy Making</topic><topic>Price regulations</topic><topic>Pricing policies</topic><topic>Public Health</topic><topic>Public Policy</topic><topic>Quality of Life Research</topic><topic>Review</topic><topic>Review Article</topic><topic>Thailand</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Espinosa, Oscar</creatorcontrib><creatorcontrib>Rodríguez-Lesmes, Paul</creatorcontrib><creatorcontrib>Romano, Giancarlo</creatorcontrib><creatorcontrib>Orozco, Esteban</creatorcontrib><creatorcontrib>Basto, Sergio</creatorcontrib><creatorcontrib>Ávila, Diego</creatorcontrib><creatorcontrib>Mesa, Lorena</creatorcontrib><creatorcontrib>Enríquez, Hernán</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>PAIS Index</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Applied health economics and health policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Espinosa, Oscar</au><au>Rodríguez-Lesmes, Paul</au><au>Romano, Giancarlo</au><au>Orozco, Esteban</au><au>Basto, Sergio</au><au>Ávila, Diego</au><au>Mesa, Lorena</au><au>Enríquez, Hernán</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges</atitle><jtitle>Applied health economics and health policy</jtitle><stitle>Appl Health Econ Health Policy</stitle><addtitle>Appl Health Econ Health Policy</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>22</volume><issue>6</issue><spage>797</spage><epage>804</epage><pages>797-804</pages><issn>1175-5652</issn><issn>1179-1896</issn><eissn>1179-1896</eissn><abstract>The article offers a comparative analysis of the influence of cost-effectiveness thresholds in the decision-making processes in financing policies, coverage, and price regulation of health technologies in nine countries. We investigated whether countries used cost-effectiveness thresholds for public health policy decision making and found that few countries have adopted the cost-effectiveness threshold as an official criterion for financing, reimbursement, or pricing. However, in countries where it is applied, such as Thailand, the results have been very favorable in terms of minimizing health technology prices and ensuring the financial sustainability of the health system. Although the cost-effectiveness threshold has opportunities for improvement, particularly in certain institutional contexts and with adequate participation of the different strategic actors in the formulation of public policy, its potential use and added value are significant in various aspects.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38995492</pmid><doi>10.1007/s40258-024-00900-5</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4893-0509</orcidid><orcidid>https://orcid.org/0000-0003-1058-3062</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1175-5652 |
ispartof | Applied health economics and health policy, 2024-11, Vol.22 (6), p.797-804 |
issn | 1175-5652 1179-1896 1179-1896 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11470905 |
source | MEDLINE; PAIS Index; SpringerNature Journals |
subjects | Clinical decision making Clinical outcomes Comparative analysis Cost analysis Cost-Benefit Analysis Costs Decision making Effectiveness GDP Gross Domestic Product Health Administration Health care expenditures Health care policy Health disparities Health Economics Health policy Health Policy - economics Health technology assessment Humans Medicine Medicine & Public Health Opportunity costs Pharmacoeconomics and Health Outcomes Policy Making Price regulations Pricing policies Public Health Public Policy Quality of Life Research Review Review Article Thailand |
title | Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A37%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Cost-Effectiveness%20Thresholds%20in%20Healthcare%20Public%20Policy:%20Progress%20and%20Challenges&rft.jtitle=Applied%20health%20economics%20and%20health%20policy&rft.au=Espinosa,%20Oscar&rft.date=2024-11-01&rft.volume=22&rft.issue=6&rft.spage=797&rft.epage=804&rft.pages=797-804&rft.issn=1175-5652&rft.eissn=1179-1896&rft_id=info:doi/10.1007/s40258-024-00900-5&rft_dat=%3Cproquest_pubme%3E3079172397%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3118852893&rft_id=info:pmid/38995492&rfr_iscdi=true |